LTBP complex-specific inhibitors of TGFβ and uses thereof

US12173059B2 · kind B2 · utility

Assignee

• Scholar Rock, Inc. · US

Inventors

• Thomas Schurpf · Cambridge, US
• Justin W. Jackson · Cambridge, US
• George Coricor · Cambridge, US
• Abhishek Datta · Boston, US
• Stefan Wawersik · Westborough, US
• Christopher Littlefield · Marblehead, US
• Adam Fogel · Watertown, US
• Caitlin Stein · Clarkston, US
• Julia McCreary · Lebanon, US
• Matthew Salotto · Hanover, US
• Frederick Streich, Jr. · Newton, US

Key dates

• Filing date: May 17, 2022
• Grant date: Dec 24, 2024
• Expiry date: Jun 14, 2043

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGFβ and/or LTBP3-TGFβ. The application also provides methods of use of these inhibitors for, for example, inhibiting TGFβ activation, and treating subjects suffering from TGFβ-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGFβ inhibitor for a subject in need thereof are also provided.